Nova Mentis Files Genetic Neuroinflammatory Disease Patent

Rhea-AI Summary

Nova Mentis Life Science Corp. (NMLSF) has filed a patent for a genetic diagnostic and therapeutic approach targeting neuroinflammatory diseases, including Fragile X syndrome and autism spectrum disorders. This innovative mRNA-based paradigm aims to assess therapeutic responses and facilitate the development of psilocybin-based treatments. Dr. Marvin S. Hausman emphasized the potential for breakthrough products in psychedelic medicine. Nova is the first biotech firm to secure psilocybin orphan drug designation in the U.S. and EU, aiming to address chronic conditions with significant unmet medical needs.

Positive

• Filed a patent for mRNA-based diagnostic and therapeutic approach targeting neuroinflammatory diseases.
• Potential for breakthrough products in psychedelic medicine.
• First biotech company to achieve psilocybin orphan drug designation in the U.S. and EU.

Negative

• None.

Messenger RNA Diagnostic/Treatment Paradigm

VANCOUVER, BC, Nov. 9, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has filed a genetic neuroinflammatory disease patent which describes a  diagnostic/therapeutic combination of mRNA molecules that encode proteins involved in the development of neurogenerative diseases, including fragile X syndrome (FXS) and autism spectrum disorders (ASD).

"The ability to penetrate the unique genetic language underlying the development of neurodegenerative chronic diseases and assess therapeutic responses opens the door for the development of breakthrough products in the field of psychedelic medicine," states Dr. Marvin S. Hausman MD, Chairman of NOVA's Scientific Advisory Board. "The clinical biomarker data generated with this genetic paradigm can be used to support the potential benefits of a psychedelic drug product IND application with U.S. FDA (1)."

(1)   https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence 

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit https://www.novamentis.ca 

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nova-mentis-files-genetic-neuroinflammatory-disease-patent-301419509.html

SOURCE Nova Mentis Life Science Corp.

FAQ

What is the recent patent filed by Nova Mentis Life Science Corp. (NMLSF)?

Nova Mentis has filed a patent for a genetic diagnostic and therapeutic approach targeting neuroinflammatory diseases.

What diseases does the new mRNA diagnostic/therapeutic patent focus on?

The patent focuses on neuroinflammatory diseases, including Fragile X syndrome and autism spectrum disorders.

What significance does the patent have for psilocybin-based treatments?

The patent is expected to support the development of psilocybin-based treatments by assessing therapeutic responses.

When did Nova Mentis Life Science Corp. announce the patent filing?

The patent filing was announced on November 9, 2021.

What is the stock symbol for Nova Mentis Life Science Corp.?

The stock symbol for Nova Mentis is NMLSF.